It has been shown that inhibiting or diminishing their expression with either SGLT-2 inhibitors or metformin could lead to favourable clinical outcomes through an improvement in endothelial function, inflammatory, and oxidative stress reduction as well as inhibition of molecular pathways that could directly lead to diabetic cardiomyopathy [14, 16, 20, 22]. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.